Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 12:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,488 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Demyelinating Disorder Clear all
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

NCT04815967
View directory record Official record
Conditions
Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury, Cervical Spinal Cord Injury, Cerebral Palsy
Interventions
Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 9, 2026, 12:13 PM EDT
Completed Phase 2 Interventional Results available

A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy

NCT03771898
View directory record Official record
Conditions
Metachromatic Leukodystrophy (MLD)
Interventions
SHP611
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Months to 72 Months
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
11
States / cities
Torrance, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 9, 2026, 12:13 PM EDT
Completed Not applicable Interventional

A Randomized Controlled Trial of a Multicomponent Walking Aid Program for People With MS

NCT04145934
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ADSTEP
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 9, 2026, 12:13 PM EDT
Completed Phase 3 Interventional

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

NCT01844232
View directory record Official record
Conditions
Multiple Sclerosis, Spasticity
Interventions
arbaclofen
Drug
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Gilbert, Arizona • Phoenix, Arizona • Pasadena, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 9, 2026, 12:13 PM EDT
Completed Phase 2 Interventional Results available

Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis

NCT02040298
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Clemastine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 9, 2026, 12:13 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

NCT01028209
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Multiple Sclerosis
Interventions
[18F] PBR06
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 9, 2026, 12:13 PM EDT
Completed Not applicable Interventional

Rhythmic Auditory Stimulation & Gait Training

NCT04314076
View directory record Official record
Conditions
Multiple Sclerosis, Gait Disorders, Neurologic
Interventions
Rhythmic auditory stimulation, Gait Training
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 9, 2026, 12:13 PM EDT
Recruiting No phase listed Observational

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

NCT06433752
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Multiple Sclerosis
Interventions
No Intervention
Other
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
109
States / cities
Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 98 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 9, 2026, 12:13 PM EDT
Active, not recruiting Not applicable Interventional

Multiple Sclerosis Falls Insight Track

NCT05837949
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MS FIT: Falls Insight Track
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 9, 2026, 12:13 PM EDT
Completed Not applicable Interventional

Effects of Meditation on Multiple Sclerosis and Peripheral Neuropathy

NCT00981643
View directory record Official record
Conditions
Multiple Sclerosis, Peripheral Neuropathy
Interventions
Meditation instruction and practice
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 9, 2026, 12:13 PM EDT
Recruiting Not applicable Interventional

Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?

NCT07225868
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Conscientiousness Coaching Before Cognitive Rehabilitation, Sham Intervention Before Cognitive Rehabilitation
Behavioral
Lead sponsor
Universiteit Leiden
Other
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 9, 2026, 12:13 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

NCT02545868
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
23-PPV, 13-PCV Booster, Influenza Vaccine, KLH, OCR, TT Vaccine
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
20
States / cities
Cullman, Alabama • Tucson, Arizona • Fullerton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 9, 2026, 12:13 PM EDT
Terminated Phase 3 Interventional Results available

Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

NCT04984278
View directory record Official record
Conditions
Spasticity With Multiple Sclerosis
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Denver, Colorado • Naples, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 9, 2026, 12:13 PM EDT
Completed No phase listed Observational Results available

A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)

NCT03933215
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cladribine
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Little Rock, Arkansas • Englewood, Colorado • Fort Collins, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 9, 2026, 12:13 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy

NCT00004418
View directory record Official record
Conditions
Adrenoleukodystrophy
Interventions
glyceryl trierucate/glyceryl trioleate
Drug
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
18 Months to 8 Years · Male only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 9, 2026, 12:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis

NCT00321568
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 9, 2026, 12:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

NCT01085318
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 9, 2026, 12:13 PM EDT
Recruiting Not applicable Interventional

High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis

NCT05735691
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
High-Intensity Treadmill Training, Treadmill Training with Perturbations, Standard Treadmill Training
Procedure
Lead sponsor
Marquette University
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Indianapolis, Indiana • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 9, 2026, 12:13 PM EDT
Completed No phase listed Observational

Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility

NCT01617395
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 9, 2026, 12:13 PM EDT
Terminated No phase listed Observational

Adherence Trial With MS LifeLines ® Services

NCT01905527
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B
Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 9, 2026, 12:13 PM EDT
Completed Phase 4 Interventional

Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations

NCT01888354
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
H.P. Acthar Gel (repository corticotropin injection)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Oceanside, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 9, 2026, 12:13 PM EDT
Completed No phase listed Observational

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis

NCT01158183
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BAY86-5046_Interferon-beta-1b
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
27
States / cities
Many Locations, Alabama • Many Locations, California • Many Locations, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2010 · Synced Oct 9, 2026, 12:13 PM EDT
Completed Phase 1 Interventional

In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging

NCT02511028
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ferumoxytol
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 9, 2026, 12:13 PM EDT
Completed No phase listed Observational

Study of myMS in Participants With a Diagnosis of Multiple Sclerosis

NCT03111394
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 9, 2026, 12:13 PM EDT